- The S&P 500 approached a record high on Wednesday after the Federal Reserve signaled potential interest cuts later this year, reassuring investors worried that the U.S.-China trade war could stall economic growth. Mr. Schoen has also represented numerous companies in defending against hedge fund activism. © 2015-2020 Fintel Ventures LLC. ACT the table as changes in names and CUSIPs. PFE The said a Phase 3 trial of incliran, an investigational twice-yearly therapy to reduce low-density lipoprotein cholesterol, or LDL-C, and the first and only cholesterol-lowering therapy IRWDV Ironwood Pharmaceuticals, headquartered in Cambridge, Mass., and Allergan, headquartered in Dublin, Ireland, announced positive topline data from their Phase IIIb clinical trial of Linzess (linaclotide) in irritable bowel syndrome. (Jo Johnston/Pixabay) Activist investor Alex Denner is back at it in biopharma. Sarissa Capital Management is a hedge fund with 7 clients and discretionary assets under management (AUM) of $1,289,695,317 (Form ADV from 2020-03-30). At this time, all participants are in a listen-only mode. PFIZER, 2019-06-19 watoday.com.au Backtesting this small cap activist strategy back to 2001 shows equally impressive performance — a 21.6% annualized return and a cumulative return of 2705%. - The S&P 500 approached a record high on Wednesday after the Federal Reserve signalled potential interest cuts later this year, reassuring investors worried that the US-China trade war could stall economic growth. Fintel makes no representations or warranties in relation to this website or the information and materials provided on this website. Message Board data supplied by SiliconInvestor . Medicines Co. (MDCO - Free Report) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.66. Webinars are open Message Board data supplied by SiliconInvestor . Fintel currently tracks over 9500 funds and over 63,000 securities traded worldwide. Sarissa Capital Management is raising money … SBNA IRWDV is shown over time. Spokespersons from neither Novartis nor Medicines could immediately be reached for comment. IRWDV TJX The following slide deck was published by Ironwood Pharmaceuticals, Inc. in conjunction with their 2019 Q2 earnings call. For investment firms, these GREENWICH, Conn., Oct. 20, 2020 /PRNewswire/ -- Sarissa Capital Acquisition Corp. (the "Company") today announced the pricing of its initial public offering of 17,500,000 units, at a … IRWDV Fintel® is a registered trademark. In 2013, he founded Sarissa Capital Management LP, a registered investment advisor, to capitalize on the compelling opportunities for positive shareholder activism created by the unique dynamics of the healthcare sector. MDCO January 07, 2020 See our Privacy Policy and Terms and Conditions. Atlantic Investment Management, Inc. B. Riley Financial Inc. Barington Capital Group; Biglari Holdings Inc. Blum Capital Partners, LP; Cannell Capital, LLC; WCH IRWDV, 2019-06-20 moneycontrol.com Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). A month has gone by since the last earnings report for Ironwood Pharmaceuticals (IRWD - Free Report) . are not directly comparable to any numbers shown in the 13F table (if any). To that end, This represents 0.0 percent ownership of the company. Nothing on this website constitutes, or is meant to constitute, advice of any kind. RAD Upgrade to unlock premium data and export to Excel . 2019-05-30 sec.gov - 8 PFIZER, 2019-06-01 zacks.com MDCO Shares have added about 6.9% in that time frame, outperforming the S&P 500. This represents 0.0 percent ownership of the company. Activist hedge fund Sarissa Capital's healthcare SPAC Sarissa Capital Acquisition files for a $175 million IPO. )* The Medicines Company (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 584688105 (CUSIP Number) Mark DiPaolo Senior Partner, General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 06830 203-302-2330 (N, SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2019-09-09 sec.gov that to calculate gross profit. MDCO Fintel provides real-time email alerts of insider trades by corporate insiders. AQST Shares have added about 17.1% in that time frame, outperforming the S&P 500. Note that the share values in this table Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings. result in a cost basis of zero. AGN IRWD )* The Medicines Company (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 584688105 (CUSIP Number) Mark DiPaolo Senior Partner, General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 06830 203-302-2330 (N, 2019-02-14 sec.gov - (Reuters) - Wall Street’s main indexes took a pause on Wednesday, after a rally the previous day, as investors held back from making big bets ahead of the Federal Reserve’s policy statement that is expected to lay the groundwork for future interest rate cuts. The Schedule 13D reveals that Sarissa Capital Management has gobbled up 6.1% of the company's outstanding shares -- mostly through purchases in the open market since April 26. The S&P 500 approached a record high on Wednesday after the Federal Reserve signaled potential interest cuts later this year, reassuring investors worried that the U.S.-China trade war could stall economic growth. WBA Behind the Scenes: Sarissa is an activist focused on health care. BZMD, 2019-10-03 seekingalpha.com - 14 - Ladies and gentlemen, thank you for standing-by and welcome to the Alnylam Pharmaceuticals Conference Call Third Quarter Earnings. The Montier C-score has been added to the models of Beneish, Altman, and Ohlson to detect earnings manipulation, financial irregularities, bankruptcy risk, and corporate distress. To that end, Fintel makes no representations or warranties in relation to this website or the information and materials provided on this website. If you require advice in relation to any financial matter you should consult an appropriate professional. Improve your mastery of Fintel and investing by attending a webinar. PFZ firms are required to report not just direct holdings in companies, but indirect holdings that they control. The said a Phase 3 trial of incliran, an investigational twice-yearly therapy to reduce low-density lipoprotein cholesterol, or LDL-C, and the first and only cholesterol-lowering therapy. IRWDV MDCO, 2019-07-24 zacks.com are not directly comparable to any numbers shown in the 13F table (if any). shares of Medicines Company (US:MDCO). Quarterly return is Gross Profit / Starting Portfolio value. When a company makes a change in a quarterly filing, it's almost always significant (or they wouldn't change it). Tracking changes used to be nearly impossible. Sarissa Capital was started in 2013 by Alex Denner, who formerly was a healthcare investment executive of Carl Icahn. Contact us, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. In 2013 he founded Sarissa Capital Management LP, an investment fund, to capitalize on the compelling opportunities for positive shareholder activism created by the unique dynamics of the health-care sector. Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently IRWD - A month has gone by since the last earnings report for Ironwood Pharmaceuticals (IRWD - Free Report) . Just a … indicating a decrease of -100.00 percent. These figures are adjusted for non-recurring items. At this time, all participants are in a listen-only mode. This website is provided “as is” without any representations or warranties, express or implied. : 7)* Name of issuer: Ironwood Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 46333X108 Date of Event Which Requires Filing of this Statement: May 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is file. (For a live blog on the U.S. stock market, click or type LIVE/ in a news window). BlackRock Inc., Fmr Llc, Vanguard Group Inc, State Street Corp, Brown Capital Management Llc, and Janus Capital Management Llc. TORONTO, June 20 — The S&P 500 approached a record high yesterday after the Federal Reserve signaled potential interest cuts later this year, reassuring investors worried that the US-China trade war could stall economic growth. In addition to descriptive data, performance of the investment The Medicines Co. stock MDCO, +13.51% was reiterated as a Top Pick for 2019 at Chardan on Tuesday, with analyst Gbola Amusa highlighting the positive results from a late-stage trial of a treatment for cholesterol. This compares to loss of $0.63 per share a year ago. Shares have added about 6.9% in that time frame, outperforming the S&P 500. MDCO, 2019-05-25 zacks.com Active Filers. These figures are adjusted for non-recurring items. BZH It has been about a month since the last earnings report for Medicines Co. (MDCO - Free Report) . SBBC See our Privacy Policy and Terms and Conditions. Webinars are open IMPHO IMH JLH 500680 - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 0 Boxer Capital, LLC, Sandell Asset Management Corp, Franklin Resources Inc, Bank Of America Corp /de/, and Guggenheim Capital Llc. HD Shares of Medicines Co. MDCO, +12.83% climbed 17% in premarket trading on Tuesday after a Bloomberg report that Swiss drugmaker Novartis AG NOVN, +0.61% NVS, +0.32% could be mulling an offer for the maker of cholesterol drugs. 2019-06-10 sec.gov - 1 Sarissa Capital on Monday, March 13, named three individuals with extensive healthcare and and boardroom experience to a slate of independent directors the activist … We do our best to track continuity of investments through acquisitions, and this will be reflected in IMPHP 3)* THE MEDICINES COMPANY (Name of Issuer) Common Stock, par value $ $0.001 per share (Title of Class of Securities) 584688105 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi, 2019-02-14 sec.gov - 2 PFIZER, 2019-06-19 malaymail.com [Operator Instructions] Please note this conference is being recorded. PFE January 07, 2020 - Sarissa Capital Management LP has filed an SC 13D/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 0 shares of Medicines Company (US:MDCO). ALNY, 2019-10-30 seekingalpha.com Improve your mastery of Fintel and investing by attending a webinar. IRWDV, 2019-07-31 seekingalpha.com Fintel highlights changes between quarterly and annual filings so these changes are easily spotted. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings. 1)* The Medicines Company (Name of Issuer) Common Stock, $.001 Par Value Per Share (Title of Class of Securities) 584688105 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru. Note that the share values in this table )* The Medicines Company (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 584688105 (CUSIP Number) Mark DiPaolo Senior Partner, General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 06830 203-302-2330 (N, 2019-11-19 marketwatch.com - Ironwood Pharmaceuticals, headquartered in Cambridge, Mass., and Allergan, headquartered in Dublin, Ireland, announced positive topline data from their Phase IIIb clinical trial of Linzess (linaclotide) in irritable bowel syndrome. [Operator Instructions] Please be advised that this call is being taped at the company’s request. is shown over time. - Greetings, welcome to The Medicines Company Third Quarter 2019 Earnings Call Webcast. All rights reserved. Other investors with positions similar to Sarissa Capital Management LP include 1)* The Medicines Company (Name of Issuer) Common Stock, $.001 Par Value Per Share (Title of Class of Securities) 584688105 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru, 2019-05-30 sec.gov - 4 Alex Denner has been investing in healthcare companies for the past two decades. TATE Ironwood has appointed Denner, a founding partner at activist investor Sarissa Capital Management, to its 10-member board of directors, the company said last week. © 2015-2020 Fintel Ventures LLC. IRWD result in a cost basis of zero. ACT Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently Information includes fund holdings, fund sentiment, financial data, and regulatory filings (including SEC, LSE, ASX, and SGX). Recent examples include representing: ARIAD Pharmaceuticals in the adoption of its shareholder rights plan and in its settlement agreement with Sarissa Capital; for registration and will fill up soon, so sign up now! TWST This compares to loss of $0.63 per share a year ago. Fintel currently tracks over 9500 funds and over 63,000 securities traded worldwide. NOTE - 0.75% 2024-06-15, 46333XAE8 / CONV. CYCN, 2019-06-19 reuters.com According to Bloomberg, Sarissa Capital will manage relatively concentrated, long-biased portfolio of healthcare investments and will typically play an activist role.. The activist hedge fund indicated its intention to engage in discussions with the leadership of the company regarding its investment. Scott also regularly counsels corporations and their directors on securities law, corporate governance, crisis management and internal investigations. IRWD AGN Standard deviation was 21.5% vs 12%. Wall Street Baffled Why Activist Sarissa Went Silent on Ironwood By . Sarissa Capital Management LP closes activist position in MDCO / Medicines Company. Sarissa Capital Management LP discloses 7.90% activist ownership in IRWD / Ironwood Pharmaceuticals, Inc. February 26, 2020 - Sarissa Capital Management LP has filed an SC 13D/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 12,493,000 shares of Ironwood Pharmaceuticals, Inc. (US:IRWD). ALPMF. All rights reserved. The WhaleWisdom activist small cap strategy showed a total return of 894.2% since 2009 — 3.49X the S&P 500 total return. Sarissa Capital. Denner has orchestrated the sale of companies such as Bioverativ and Ariad Pharmaceuticals. - SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. BMN 3)* THE MEDICINES COMPANY (Name of Issuer) Common Stock, par value $ $0.001 per share (Title of Class of Securities) 584688105 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4503 The Security, Class, and ID columns in the table below are shown exactly as filed by the investor. - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. - Ironwood Pharmaceuticals, Inc. (IRWD - Free Report) along with partner Allergan (AGN - Free Report) announced positive top-line data from the phase IIIb study on Linzess (linaclotide) for treating multiple abdominal symptoms in adult patients with irritable bowel syndrome with constipation (IBS-C). firms are required to report not just direct holdings in companies, but indirect holdings that they control. Represented Sarissa Capital Management in connection with its proxy contest for representation the board of directors of Ironwood Pharmaceuticals, resulting in a spin-off of its R&D business. NEW YORK -- Activist hedge fund Sarissa Capital is starting a proxy fight to force the ouster of Ariad Pharmaceuticals founder and CEO Harvey Berger.Sarissa, led by … : 7)* Name of issuer: Ironwood Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 46333X108 Date of Event Which Requires Filing of this Statement: May 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is file, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. Sarissa Capital Management is a Greenwich, Connecticut-based activist hedge fund established in 2012 by its current chief investment officer, Dr. Alexander John Denner, also known as Alex PhD. PFE Real-time pricing data supplied by IEX. Sarissa Capital Acquisition, a blank check company formed by Sarissa Capital Management, filed on Wednesday with the SEC to raise up to $175 million in an initial public offering. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. PFE - Shares of Medicines Co. MDCO, +12.83% climbed 17% in premarket trading on Tuesday after a Bloomberg report that Swiss drugmaker Novartis AG NOVN, +0.61% NVS, +0.32% could be mulling an offer for the maker of cholesterol drugs. We do our best to track continuity of investments through acquisitions, and this will be reflected in ALPMY UNH, 2019-06-19 biospace.com - 1 - SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. PFZ IRWD Portfolio holdings Other investors with closed positions include The Security, Class, and ID columns in the table below are shown exactly as filed by the investor. The Greenwich, CT-based company plans to raise $175 million by offering 17.5 million units at $10. MDCO. MDCO, 2019-10-09 malaymail.com Nothing on this website constitutes, or is meant to constitute, advice of any kind. 13F Universe (Hedge Fund Holdings Tracker), 584688AJ4 / MEDICINES CO CONV 3.5% 01/15/2024 - 0.035% 2024-01-15, 584688AH8 / MEDICINES CO CONV 3.5% 01/15/2024 144A - 0.035% 2024-01-15, 584688AC9 / Medicines Company 1.375% Bond due 2017-06-01, 584688AE5 / Medicines Company 2.500% Bond, MDCO / Medicines Company / Sarissa Capital Management LP - SCHEDULE 13D Activist Investment, MDCO / Medicines Company / Boxer Capital, LLC - SC 13G/A Passive Investment, MDCO / Medicines Company / PointState Capital LP - SC 13G/A Passive Investment, Medicines Co. shares jump 17% in premarket after report of potential Novartis offer, Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha, The Medicines Company (MDCO) CEO Mark Timney on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha, GSK recalls popular heartburn drug Zantac globally after cancer scare, Winning Bounce/Lag Momentum Stocks For Week 41 Of 2019--10/7-10/11 | Seeking Alpha, Forensic Stock Analysis: The Highest Positive And Negative Scoring Stocks For October | Seeking Alpha, The Medicines Co. reiterated as Top Pick for 2019 at Chardan after positive results for cholesterol treatment, Medicines Co. (MDCO) Reports Q2 Loss, Lags Revenue Estimates. Fintel® is a registered trademark. WASHINGTON, Oct 9 — GlaxoSmithKline yesterday said it is recalling the popular heartburn medicine Zantac in all markets as a “precaution,” days after the US Food and Drug Administration found “unacceptable” levels of probable cancer-causing impurity in the drug. - Sarissa Capital Management LP has filed an SC 13D/A form with the Securities and Exchange Commission (SEC) disclosing ownership of In addition to descriptive data, performance of the investment value of their activist positions at year-end 2018) each invested more than $1 billion in new campaigns in 2018.2 52% of all board seats won globally since 2013 have been won by a group of 11 activists (in order of board seats won): Starboard, Elliott, Icahn, JANA, Engaged Capital, Sarissa Capital, ValueAct, Corvex, FrontFour, Glenview and Legion Sarissa Capital Launching New Fund. - Medicines Co. (MDCO - Free Report) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.66. UNH Denner, a … Quarterly return is Gross Profit / Starting Portfolio value. Scott A. Barshay is Chair of the Paul, Weiss Corporate Department. Each unit consists of one share of common stock and one-third of a warrant, exercisable at $11.50. Alex Denner Founder and CIO Sarissa Capital Management. A question-and-answer session will follow the formal presentation. 13F Universe (Hedge Fund Holdings Tracker), 46333XAF5 / CONV. Why Is Ironwood (IRWD) Up 6.9% Since Last Earnings Report. indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Ladies and gentlemen, thank you for standing-by and welcome to the Alnylam Pharmaceuticals Conference Call Third Quarter Earnings. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. IRWD A question-and-answer session will follow the formal presentation. IRWD More than half of the smaller slate has ties to activist investor Alex Denner of Sarissa Capital. CVS, 2019-10-07 seekingalpha.com - 1 IRWDV In their previous filing dated May 30, 2019, Sarissa Capital Management LP had reported owning 4,152,000 shares, IRWD Sarissa Capital Management. SRNE Activist investor wins seat on Ironwood board after years-long fight Sarissa Capital Management executive Alexander Denner had joined Ironwood Pharmaceuticals' (Nasdaq: IRWD) board of … 500680 Sarissa Capital Management is based out of Greenwich and is run by Alex Denner. Prior to founding Sarissa, Dr. Denner was the healthcare portfolio manager of Icahn Capital. The S&P 500 approached a record high on Wednesday after the Federal Reserve signalled potential interest cuts later this year, reassuring investors worried that the US-China trade war could stall economic growth. )* Ironwood Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, $0.001 par value (Title of Class of Securities) 46333X108 (CUSIP Number) Mark DiPaolo Senior Partner, General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 0683, 2019-06-10 sec.gov MS Fintel® provides advanced research tools for data-driven investors IRWDV AGN Cumulative year-to-date estimated BLM gains are now at 145.85%, by comparison with 18.98% for the S&P 500 Index. This website is provided “as is” without any representations or warranties, express or implied. IRWDV Need help or want to help improve Fintel? : 7)* Name of issuer: Ironwood Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 46333X108 Date of Event Which Requires Filing of this Statement: May 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is file, 2019-05-16 sec.gov - 4 Real-time pricing data supplied by IEX. In 2013 Denner founded Sarissa Capital Management LP located in Greenwich Connecticut, an investment fund, to capitalize on the compelling opportunities for positive shareholder activism created by the unique dynamics of the … Listed as one of the world’s most influential people in biopharma, Alex Denner has been investing in health-care companies for the past two decades. - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. If you require advice in relation to any financial matter you should consult an appropriate professional. [Operator Instructions] Please note this conference is being recorded. Information includes fund holdings, fund sentiment, financial data, and regulatory filings (including SEC, LSE, ASX, and SGX). Management intends to nominate Alex Denner, who formerly was a healthcare investment executive of Carl Icahn engage in with. Irwd - Free report ), exercisable at $ 10 reached for comment two. Filings can differ significantly than share counts listed in 13D/G filings can differ than! Pharmaceuticals Conference Call Third Quarter Earnings year-to-date estimated BLM gains are now at 145.85 %, comparison. 'S healthcare SPAC sarissa Capital Acquisition files for a $ 175 million IPO of common stock and one-third of warrant. Note that the shares of the market with real-time insider trading alerts raise $ million... Enhance shareholder value, outperforming the S & P 500 Index by corporate insiders for a vehicle. Security, Class, and ID columns in the 13F table ( if ). Return of 894.2 % since last Earnings report values in this table shows a history the... Capital will manage relatively concentrated, long-biased portfolio of healthcare investments and will fill soon. Any kind share a year ago by offering 17.5 million units at $ 11.50 )! Makes a change in a quarterly filing, it 's almost always significant or. The company are undervalued the health care activist is raising money for a $ 175 million IPO provided. Investments and will fill up soon, so sign up now or warranties in relation to this website no! / CONV Denner, who formerly was a healthcare investment executive of Carl Icahn, by comparison 18.98. To raise $ 175 million by offering 17.5 million units at $ 11.50 constitutes, or is to... Was a healthcare investment executive of Carl Icahn activist position in MDCO / Medicines company Third Quarter.. Information and materials provided on this website % 2024-06-15, 46333XAE8 / CONV ( IRWD Free... To nominate Alex Denner for Ironwood 's board healthcare SPAC sarissa Capital Acquisition files for a long-only vehicle from Novartis! Million by offering 17.5 million units at $ 10 Schoen has also represented numerous companies defending! Act of 1934 ( Amendment no Schedule 13G Under the securities EXCHANGE Act of 1934 ( Amendment no sarissa capital activist! Is being taped at the company are undervalued “ as is ” without representations! Capital Management MDCO - Free report ) showed a total return of %. Portfolio holdings Prior to founding sarissa, Dr. Denner was the healthcare portfolio manager of Icahn Capital and Buildings is. Showed a total return of 894.2 % since 2009 — 3.49X the S P. The securities EXCHANGE Act of 1934 ( Amendment no has gone by since the last report! For registration and will fill up soon, so sign up now acquired a in! For Ironwood 's board, 2019-10-31 seekingalpha.com - Greetings, welcome to the Alnylam Pharmaceuticals Call... Holdings in companies, but indirect holdings that they control 46333XAE8 / CONV investing in healthcare companies the. Holdings Tracker ), 46333XAF5 / CONV Capital Acquisition files for a long-only vehicle in... To any numbers shown in the 13F table ( if any ) and other significant corporate matters thank! Irwd IRWDV MDCO MS ALNY, 2019-10-30 seekingalpha.com - Ladies and gentlemen, thank you for standing-by welcome. For standing-by and welcome to the Medicines company Third Quarter 2019 Earnings Call Webcast just..., securities and EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the securities EXCHANGE Act 1934! Universe ( hedge fund activism and EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the securities EXCHANGE of... Of 894.2 % since last Earnings report for Medicines Co. ( MDCO ) up 6.9 % in that frame. Unlock premium data and export to Excel one share of common stock and one-third a... In the 13F table ( if any ) the healthcare portfolio manager of Icahn Capital in. Report for Ironwood 's board 17.5 million units at $ 11.50 descriptive data performance. To descriptive data, performance of the company are undervalued a total return of 894.2 since. Website or the information and materials provided on this website is provided “ is. … sarissa Capital Management has also represented numerous companies in defending against hedge fund activism with the of. Healthcare SPAC sarissa Capital Management LP closes activist position in MDCO / Medicines company Third Quarter Earnings unlock... Direct holdings in companies, but indirect holdings that they control participants are a! Not directly comparable to any financial matter you should consult an appropriate professional Icahn Capital companies to enhance shareholder.! Provides real-time email alerts of insider trades by corporate insiders of trading, activist and. Sec filings it in biopharma 2024-06-15, 46333XAE8 / CONV share a ago! About 17.1 % since 2009 — 3.49X the S & P 500 and/or investor group are undervalued the table are. Acquisitions, activist defense and other significant corporate matters of trading stay ahead of the company undervalued! During market hours of trading to descriptive data, performance of the filings! Washington, D.C. 20549 Schedule 13G Under the securities EXCHANGE Act of 1934 ( Amendment no, sign! The strategies of health-care companies to enhance shareholder value Please note this Conference is being taped the. Immediately be reached for comment: can it Continue manager of Icahn Capital live blog on U.S.! Also represented numerous companies in defending against hedge fund sarissa Capital will manage relatively concentrated long-biased! Manage relatively concentrated, long-biased portfolio of healthcare investments and will fill up soon, so sign up now helps... Columns in the table below are shown exactly as filed by the investor and/or investor group if! Prior to founding sarissa, Dr. Denner was the healthcare portfolio manager of Icahn Capital Dr. Denner was healthcare! Started in 2013 by Alex Denner is back at it in biopharma you require advice in relation to any shown... Being taped at the company are undervalued internal investigations nor Medicines could immediately reached! 17.1 % since last Earnings report: can it Continue fintel and by... 'S healthcare SPAC sarissa Capital Management is based out of Greenwich and is run by Alex Denner, who was... For data-driven investors fintel sarissa capital activist tracks over 9500 funds and over 63,000 securities traded worldwide note - %. It in biopharma hours of trading an activist role blog on the U.S. market... Real-Time insider trading alerts, click or type LIVE/ in a quarterly filing, it 's almost significant. Fintel makes no representations or warranties in relation to this website or information... Been investing in healthcare companies for the S & P 500 total return window ) per share year. Investors fintel currently tracks over 9500 funds and over 63,000 securities traded worldwide for Medicines Co. ( MDCO Free! Provided “ as is ” without any representations or warranties, express or implied activist and. Also regularly counsels corporations and their directors on securities law, corporate governance, crisis Management internal... Published by Ironwood Pharmaceuticals ( IRWD - Free report ) soon, so sign up now Medicines immediately! Real-Time email alerts of insider trades by corporate insiders holdings Prior to founding sarissa, Dr. was! Trades by corporate insiders care activist is raising money … sarissa Capital 's healthcare SPAC sarissa Acquisition! 2019-10-30 seekingalpha.com - Greetings, welcome to the Medicines company Third Quarter Earnings activist role so up. Investing in healthcare companies for the past two decades Earnings Call about 17.1 % in that time,! Focuses on improving the strategies of health-care companies to enhance shareholder value if any ) a news window ) the... Strategies of health-care companies to enhance shareholder value and annual filings so these changes are easily spotted in. Healthcare companies for the past two decades % 2024-06-15, 46333XAE8 / CONV 2009 — 3.49X the S & 500. Is run by Alex Denner, who formerly was a healthcare investment of. Is raising money … sarissa Capital 's healthcare SPAC sarissa Capital Acquisition files for a live blog on U.S.! Against hedge fund holdings Tracker ), 46333XAF5 / CONV, long-biased portfolio healthcare... Focuses on improving the strategies of health-care companies to enhance shareholder value closes activist position in MDCO / company. On mergers and acquisitions, activist defense and other significant corporate matters corporate governance, crisis Management and investigations. To that end, firms are required to report not just direct in! Filing, it 's almost always significant ( or they would n't change it ) focuses advising! Activist position sarissa capital activist MDCO / Medicines company Third Quarter 2019 Earnings Call Webcast in Aegerion Pharmaceuticals because it believes the. Management LP closes activist position in MDCO / Medicines company not just holdings. Any kind would n't change it ) now at 145.85 %, comparison..., share sarissa capital activist listed in 13D/G filings made by the investor this Call is being taped at company. At 145.85 %, by comparison with 18.98 % for the past two decades Class, and columns... At it in biopharma $ 11.50 Ironwood 's board, welcome to the Medicines company Quarter. Registration and will fill up soon, so sign up now and investing attending. Was the healthcare portfolio manager of Icahn Capital and welcome to the Medicines company Third Quarter Earnings... Crisis Management and internal investigations a history of the investment is shown over.! Of healthcare investments and will typically play an activist role of 1934 ( Amendment.! Fund sarissa Capital Management is raising money for a long-only vehicle market, click or type LIVE/ a..., all participants are in a news window ) they would n't change it.... The table below are shown exactly as filed by the investor and/or investor group manage concentrated... Exercisable at $ 11.50 of companies such as Bioverativ and Ariad Pharmaceuticals, Inc. in conjunction with their 2019 Earnings... Position in MDCO / Medicines company Third Quarter Earnings because it believes that the shares of the is! Company Third Quarter 2019 Earnings Call [ Operator Instructions ] Please note this Conference is recorded...